Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul 25;8(30):49370-49379.
doi: 10.18632/oncotarget.17217.

Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program

Juanjuan Li  1 , Yue Xia  2 , Qi Wu  1 , Shan Zhu  1 , Chuang Chen  1 , Wen Yang  1 , Wen Wei  1 , Shengrong Sun  1
Affiliations

Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program

Juanjuan Li et al. Oncotarget. .

Abstract

Background: The aim of this study was to evaluate the outcomes of patients with inflammatory breast cancer (IBC), with emphasis on the role of molecular subtypes and radiotherapy.

Methods: A retrospective cohort study to investigate overall survival (OS) and breast cancer-specific mortality (BCSM) in patients with IBC was conducted using data obtained by the Surveillance, Epidemiology, and End Results (SEER) program from 2010-2013. Cox multivariate regression was used to calculate the adjusted Hazard Ratios (aHR).

Results: 403 patients were eligible for this study. Patients in the group with hormone receptors (HR)+/HER2- subtype had an OS of 79.6% compared with 89.0 % in the group with (HR)+/HER2+ subtype and 76.8% in the HR-/HER2+ group and 62.9% in the triple-negative (TN) group. BCSM was 16.3% for the HR+/HER2- group, 9.8% for the HR+/HER2+ group, 21.7% for the HR-/HER2+ group, and 30.5% for the TN group. For distant metastases, the results showed that there was a high probability of bone metastasis in HR-positive groups, brain and liver metastasis in HER2-positive groups, and lung metastasis in the TN group. Multivariate analysis demonstrated that estrogen receptor and HER2 positivity were associated with better survival and that the TN subtype had a poorer OS and BCSM compared with other subtypes (P<0.05). Furthermore, patients who received radiotherapy were more likely to have improved survival (P< 0.05).

Conclusion: Inflammatory breast cancer appears to alter the prognosis in association with the receptor status and molecular subtypes. Radiotherapy was still considered to be a crucial treatment for patients with IBC.

Keywords: SEER program; inflammatory breast cancer; molecular subtypes; outcomes.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1. Weighted Kaplan–Meier curves of overall survival (OS) and breast cancer-specific mortality (BCSM) based on the HER2 status
(A) OS is based on the HER2 status. (B) BCSM is based on the HER2 status.
Figure 2
Figure 2. Weighted Kaplan–Meier curves of overall survival (OS) and breast cancer-specific mortality (BCSM) based on the molecular subtypes
(A) OS is based on the molecular subtypes. (B) BCSM is based on the molecular subtypes.
Figure 3
Figure 3. Weighted Kaplan–Meier curves of overall survival (OS) and breast cancer-specific mortality (BCSM) based on radiotherapy
(A) OS is based on radiotherapy. (B) BCSM is based on radiotherapy.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30. - PubMed
    1. Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, Krishnamurthy S, Le-Petross H, Bidaut L, Player AN, Barsky SH, Woodward WA, Buchholz T, et al. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin. 2010;60:351–375. - PubMed
    1. Dushkin H, Cristofanilli M. Inflammatory breast cancer. J Natl Compr Canc Netw. 2011;9:233–240. quiz 241. - PubMed
    1. Anderson WF, Chu KC, Chang S. Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? J Clin Oncol. 2003;21:2254–2259. - PubMed
    1. Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM, Ueno NT. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? Oncotarget. 2015;6:12890–12908. doi: 10.18632/oncotarget.3849. - DOI - PMC - PubMed

MeSH terms